Literature DB >> 2243138

A phosphatase activity present in peripheral blood myeloid cells of chronic myelogenous leukemia patients but not normal individuals alters nuclear protein binding to transcriptional enhancers of interferon-inducible genes.

D C Seong1, S Sims, E Johnson, O M Howard, B Reiter, J Hester, M Talpaz, H Kantarjian, A Deisseroth.   

Abstract

Cytoplasmic protein from peripheral blood myeloid cells of chronic myelogenous leukemia (CML) patients altered the electrophoretic mobility of complexes formed between nuclear proteins and interferon-inducible transcriptional enhancers. Immature myeloid marrow cells (blasts and promyelocytes) have a higher level of this activity than do mature myeloid marrow cells (bands and polys). This activity, which is not detectable in the peripheral blood cells of normal individuals, is at least 50-fold higher in CML marrow blasts and promyelocytes than that found in marrow blasts and promyelocytes of normal individuals. This activity was inhibited by in vivo incubation of immature myeloid cells with the phosphatase inhibitor, sodium orthovanadate (0.2 mM), and by adding orthovanadate (20 mM) directly to cytoplasmic proteins of myeloid cells. Interferon-alpha (1,000 U/ml) reduced the effects of the CML myeloid cell cytoplasmic protein on the electrophoretic mobility of nuclear protein-DNA complexes. These data suggest that a unique phosphatase may be involved in the abnormalities in CML which are modulated by interferon-alpha.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243138      PMCID: PMC296917          DOI: 10.1172/JCI114889

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Use of a protein-blotting procedure and a specific DNA probe to identify nuclear proteins that recognize the promoter region of the transferrin receptor gene.

Authors:  W K Miskimins; M P Roberts; A McClelland; F H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

2.  Temperature-sensitive mutant of avian erythroblastosis virus suggests a block of differentiation as mechanism of leukaemogenesis.

Authors:  T Graf; N Ade; H Beug
Journal:  Nature       Date:  1978-10-12       Impact factor: 49.962

3.  Marrow transplantation for the treatment of chronic myelogenous leukemia.

Authors:  E D Thomas; R A Clift; A Fefer; F R Appelbaum; P Beatty; W I Bensinger; C D Buckner; M A Cheever; H J Deeg; K Doney
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

4.  Interferon affects nuclear proteins in cells of clinically sensitive chronic myelogenous leukemia patients.

Authors:  O M Howard; M Talpaz; H Kantarjian; D Seong; A Wedrychowski; N Paslidis; J Hester; A Cork; J Turpin; G Lopez-Berestein
Journal:  Blood       Date:  1990-09-15       Impact factor: 22.113

5.  Tyrosylprotein kinase and phosphatase activities in membrane vesicles from normal and Rous sarcoma virus-transformed rat cells.

Authors:  B Gallis; P Bornstein; D L Brautigan
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

6.  Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate.

Authors:  G Swarup; S Cohen; D L Garbers
Journal:  Biochem Biophys Res Commun       Date:  1982-08       Impact factor: 3.575

7.  Cytosolic protein phosphotyrosine phosphatases from rabbit kidney. Purification of two distinct enzymes that bind to Zn2+-iminodiacetate agarose.

Authors:  C L Shriner; D L Brautigan
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

8.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

9.  Phosphotyrosyl-protein phosphatase. Specific inhibition by Zn.

Authors:  D L Brautigan; P Bornstein; B Gallis
Journal:  J Biol Chem       Date:  1981-07-10       Impact factor: 5.157

10.  Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

Authors:  M Talpaz; H M Kantarjian; K McCredie; J M Trujillo; M J Keating; J U Gutterman
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245

View more
  1 in total

1.  Altered Ca2+ homeostasis in polymorphonuclear leukocytes from chronic myeloid leukaemia patients.

Authors:  Chetana M Revankar; Suresh H Advani; Nishigandha R Naik
Journal:  Mol Cancer       Date:  2006-11-27       Impact factor: 27.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.